No Data
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Institutions Along With Retail Investors Who Hold Considerable Shares InAdicet Bio, Inc. (NASDAQ:ACET) Come Under Pressure; Lose 29% of Holdings Value
Key Insights The considerable ownership by retail investors in Adicet Bio indicates that they collectively have a greater say in management and business strategy The top 8 shareholders own 51% of th
Express News | Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Express News | Adicet Today Presented Abstract Featuring Preclinical Data Highlighting ADI-270 At ASGCT27th Annual Meeting
Express News | Adicet Bio Inc - Preclinical Findings Showed Robust Anti-Tumor Activity of Adi-270 in Multiple Cd70-Positive Solid and Hematological Cancer Models
Express News | Adicet Bio Inc - on Track to File an Investigational New Drug (Ind) Application for Adi-270 in 2Q 2024